Daiichi Sankyo opens subsidiary in Puerto Rico
This article was originally published in Scrip
Executive Summary
Daiichi Sankyohas opened a subsidiary in Puerto Rico, the company announced yesterday. Daiichi Sankyo de Puerto Rico, based in San Juan, will act as a sales agent for its parent company. Its regional director Jose Vasquez said that the new subsidiary marked the company's growth, fuelled by its expanding portfolio and robust pipeline of new compounds. Daiichi Sankyo is currently focusing its R&D on cardiovascular and metabolic disease. Its marketed products centre on hypertension, cholesterol and type 2 diabetes.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.